Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.
- DOI
- 10.1111/cts.13879
- Published
- 2024 Jul
- Container
- Clinical and translational science
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/cts.13879,
title = {Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.},
author = {Hakariya H and Moriarty F and Ozaki A and Mulinari S and Saito H and Tanimoto T},
year = {2024},
journal = {Clinical and translational science},
doi = {10.1111/cts.13879},
url = {https://doi.org/10.1111/cts.13879}
}RIS
TY - JOUR TI - Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals. AU - Hakariya H AU - Moriarty F AU - Ozaki A AU - Mulinari S AU - Saito H AU - Tanimoto T PY - 2024 JO - Clinical and translational science DO - 10.1111/cts.13879 UR - https://doi.org/10.1111/cts.13879 ER -
APA
H, H., F, M., A, O., S, M., H, S., & T, T. (2024). Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals.. Clinical and translational science. https://doi.org/10.1111/cts.13879
Source records
- pubmed · retrieved 2026-09-26T16:50:43.738Z